Brief: Sino Biopharmaceutical Says Voluntary Announcement Approval Of Clinical Trial For TQB3015
28/11/2023 10:18
Nov 28 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* VOLUNTARY ANNOUNCEMENT APPROVAL OF CLINICAL TRIAL FOR
TQB3015
* TQB3015 "ATR KINASE INHIBITOR" TABLET APPROVED BY NMPA OF
CHINA
TO COMMENCE CLINICAL TRIALS FOR TREATMENT OF MALIGNANT TUMOR
Source text for Eikon: ID:
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up